Harbourvest Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GENB
Generate Biomedicines
GENB
|
+$21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rubrik
RBRK
|
+$6.9M |
| 2 |
Epsilon Energy
EPSN
|
+$3.9M |
| 3 |
RPTX
Repare Therapeutics
RPTX
|
+$31.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 65.17% |
| 2 | Healthcare | 26.96% |
| 3 | Technology | 7.88% |
| 4 | Energy | 0% |
No holdings matched the selected filter criteria.
Similar funds
Harbourvest Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Harbourvest Partners held 8 positions worth $101M, down 42% from $174M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Harbourvest Partners deployed $10.2M of net new capital in Q1 2026, opening 1 new position. Its largest new stake was Generate Biomedicines: 1,722,210 shares worth $21.5M.
By sector, the portfolio is most concentrated in Financials at 65% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the most notable exit was Rubrik, an estimated $6.9M sold.
- Harbourvest Partners's largest Q1 2026 buy was Generate Biomedicines: 1,722,210 shares worth $21.5M.
- Harbourvest Partners fully exited Rubrik in Q1 2026, selling an estimated $6.9M.
- Harbourvest Partners's ten largest holdings make up 100% of its $101M portfolio in Q1 2026.
- Harbourvest Partners opened 1 new position and closed 3 in Q1 2026.
- Harbourvest Partners's portfolio value fell 42% quarter-over-quarter to $101M.
Based on Harbourvest Partners's 13F filing for Q1 2026, filed 15 May 2026.